Skip to main content

Fetroja Side Effects

Generic name: cefiderocol

Medically reviewed by Last updated on Jan 9, 2024.

Note: This document contains side effect information about cefiderocol. Some dosage forms listed on this page may not apply to the brand name Fetroja.

Applies to cefiderocol: intravenous powder for solution.

Serious side effects of Fetroja

Along with its needed effects, cefiderocol (the active ingredient contained in Fetroja) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking cefiderocol:

Less common

Incidence not known

Other side effects of Fetroja

Some side effects of cefiderocol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to cefiderocol: intravenous powder for injection.


Very common (10% or more): Elevated liver tests (including increased ALT, increased AST, increased GGT, increased blood alkaline phosphatase, increased hepatic enzyme, increased liver function test, abnormal liver function test, increased transaminases, hypertransaminasemia; up to 16%)

Common (1% to 10%): Increased ALT, increased GGT, increased AST, abnormal hepatic function (including increased liver function test, increased hepatic enzyme, increased transaminases, abnormal liver function test)

Frequency not reported: Cholelithiasis, cholecystitis, gallbladder pain, cholestasis[Ref]


Very common (10% or more): Hypokalemia (including decreased blood potassium; up to 11%)

Common (1% to 10%): Hypomagnesemia

Frequency not reported: Decreased appetite, hypocalcemia, fluid overload, hyperkalemia[Ref]


Common (1% to 10%): Diarrhea, vomiting, nausea, constipation, Clostridioides difficile colitis (including pseudomembranous colitis, C difficile infection)

Frequency not reported: Abdominal pain, dry mouth, stomatitis, C difficile-associated diarrhea, oral candidiasis[Ref]


Common (1% to 10%): Atrial fibrillation

Frequency not reported: Congestive heart failure, bradycardia, myocardial infarction, atrial flutter[Ref]


Common (1% to 10%): Infusion site reactions (including infusion site erythema, inflammation, pain, pruritus, injection site pain, phlebitis, infusion site pain, injection site phlebitis)[Ref]


Common (1% to 10%): Rash (including macular rash, maculopapular rash, erythema, skin irritation, erythematous rash, drug eruption)

Frequency not reported: Pruritus

Beta-lactam antibacterial drugs:

-Frequency not reported: Serious skin reactions[Ref]

Nervous system

Common (1% to 10%): Headache

Frequency not reported: Dysgeusia, seizure


-Frequency not reported: Seizures triggered, nonconvulsive status epilepticus, encephalopathy, coma, asterixis, neuromuscular excitability, myoclonia[Ref]


Common (1% to 10%): Candidiasis (including oral candidiasis, vulvovaginal candidiasis, candiduria, candida infection)

Frequency not reported: Pyrexia, peripheral edema, C difficile infection, increase in all-cause mortality, death[Ref]


Common (1% to 10%): Cough

Frequency not reported: Dyspnea, pleural effusion[Ref]


Uncommon (0.1% to 1%): Hypersensitivity (including skin reactions, pruritus)

Frequency not reported: Drug hypersensitivity

Beta-lactam antibacterial drugs:

-Frequency not reported: Serious and sometimes fatal hypersensitivity (anaphylactic) reactions[Ref]


Frequency not reported: Thrombocytosis, thrombocytopenia, prolonged prothrombin time (PT), prolonged PT-INR, prolonged activated partial thromboplastin time[Ref]


Frequency not reported: Acute interstitial nephritis


Frequency not reported: Insomnia, restlessness[Ref]


Frequency not reported: Increased creatine phosphokinase[Ref]


Frequency not reported: RBC urine positive[Ref]


1. Cerner Multum, Inc. "UK Summary of Product Characteristics."

2. (2019) "Product Information. Fetroja (cefiderocol)." Shionogi USA Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.